Additionally, studies show that tipifarnib suppresses tumour aggressiveness in several malignancies and low-dose tipifarnib had antitumour effects only on HIF-1α-positive cells through the mTOR singling pathway, both in vitro and in vivo in GC model 43. Here, HIF1A is linked to gastric cancer.